Combining trabectedin and olaparib showed marginal improvement in progression-free survival for advanced soft tissue sarcomas, with notable benefits in specific subgroups. Patients with PARP1 ...
A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...
or on the link below. Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated ...
A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib. Objective: To assess the effects of a nurse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results